Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Psoriasis

How to keep your summer skin problems under control as many avoid leaving house

Eczema, vitiligo, prickly heat, sunscreen sensitivity, acne and psoriasis can become a real misery as the days get longer, hotter and stickier in the summer

Daily Mirror

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Benzinga

Nurse, 22, had sore throat which led to her developing scaly 'leopard print skin'

Ashling Armstrong, a 22-year-old nurse from Belfast, developed a sore throat which doctors said triggered Guttate psoriasis, a skin condition which left her with "scaly" skin

Daily Mirror

From analysis to the latest developments in health,
read the most diverse news in one place.

Nurse, 22, says sore throat left her with 'leopard print skin'

Ashling Armstrong says she gets people staring 'everyday' at her skin

Manchester Evening News

Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial

Can-Fite BioPharma Ltd (NYSE:CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis. The study data show that patients treated with oral Piclidenoson 2 mg or 3 mg twice daily had clinically equivalent efficacy responses. At week 16, patients receiving…

Benzinga

Soligenix Gets FDA Nod For Mid-Stage Psoriasis Study

The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s (NASDAQ: SNGX) Investigational New Drug (IND) application for Phase 2a clinical trial Evaluating SGX302 in the treatment of patients with Mild-to-Moderate Psoriasis.

Benzinga

Mum given devastating choice between life-changing medication and having a baby

Rebecca Sayers suffers from the lifelong chronic skin condition psoriasis

Chronicle Live

Read news from The Economist, FT, and more,
with one subscription

Student blames horrific 'red raw' sores covering 90% of body on sharing vapes with pals

Emily Angel Pellegrini, 21, visited the doctor after she first noticed a tiny scab under her boob at the start of the year but just dismissed it as friction from her bra

Daily Mirror

Letter: Lady Knight of Collingtree obituary

Ray Jobling writes: Jill Knight made a great contribution to the Psoriasis Association

The Guardian - UK

Can-Fite Q1 Revenue Increases 38.5%, Phase III Psoriasis Treatment Study Results Expected In Q2

Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) released financial results for the quarter ended March 31, 2022, revealing revenue of $200,000, an increase of or 38.5%, compared to $150,000 in Q1 2021. Q1 Financial Highlights

Benzinga

This Mid-Cap Firm Can Potentially Offer Biggest Oral Drug In Atopic Dermatitis, Cantor Thinks So

Cantor assumes coverage of RAPT Therapeutics Inc (NASDAQ:RAPT) with an Overweight rating and a price target of $44 (vs. $58 previously). The analyst says the company's RPT193 (lead inflammation drug) could be a $3 billion drug in just atopic dermatitis (AD) indication, as it expects AD to outperform psoriasis. Cantor suggests that ‘193 is…

Benzinga

SNGX: Phase 2a Trial of SGX302 in Psoriasis to Initiate in Second Half of 2022…

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT

Benzinga

Irishman went from clear skin to Psoriasis overnight but has found a way to 'control' how he looks

Damien Broderick, 30, said he woke up one day as a teenager and from his neck to his waist was "one big red, raw, flaky, scale"

Irish Mirror

BVXV: Definitive Collaboration Agreement Signed to Develop Pipeline of NanoAb Therapies…

By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers

AnaptysBio Inc (NASDAQ:ANAB) announced topline data from a Phase 1 trial of ANB032, an anti-BTLA agonist antibody. Topline data demonstrated favorable safety, tolerability, and rapid and sustained pharmacokinetics and pharmacodynamic profile, supporting the advancement of ANB032 into subsequent patient trials. ANB032 was generally well-tolerated, and no dose-limiting toxicities were observed. The Company said…

Daily Record

Scots make-up artist with 'zombie' psoriasis helping others to transform problem skin

Talented Danielle Robertson was diagnosed with psoriasis aged 16 and has endured crippling flare-ups ever since.

1 2 3 4

People

David Bautz

41 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Kennedy News and Media

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.